微创玻璃体切割手术联合康柏西普玻璃体腔注射治疗增生性糖尿病视网膜病变的临床效果

Clinical effect on the treatment of proliferative diabetic retinopathy with minimally invasive vitrectomy combined with compexip vitreous injection

目的探讨微创玻璃体切割手术联合康柏西普玻璃体腔注射治疗增生性糖尿病视网膜病变的优势及效果。方法选择2020年3月至2022年10月沭阳医院收治的66例增生性糖尿病视网膜病变患者为研究对象,以随机数表法分为两组,对照组(33例)患者采取微创玻璃体切割手术治疗;观察组(33例)患者在对照组基础上予以药物注射治疗(康柏西普玻璃体腔注射)。比较两组眼部指标及围手术期临床指标。结果治疗前,两组患者视力、眼压、黄斑中心凹厚度比较,差异无统计学意义(P>0.05);治疗后两组眼部指标均较治疗前改善,且观察组患者在视力提升、眼压下降及黄斑中心凹厚度减少方面与对照组比较,差异有统计学意义(P<0.05)。观察组患者手术、术后水肿吸收、眼底出血吸收和渗出液吸收用时及术中出血量均少于对照组,差异有统计学意义(P<0.05)。结论对于增生性糖尿病视网膜病变的患者经过联合方案,即微创玻璃体切割手术联合玻璃体腔内注射药物(康柏西普)进行治疗,其疗效确切,可有效促进患者视力恢复,调节眼压,值得运用推广。

Objective To investigate the advantages and efficacy of minimally invasive vitrectomy combined with vitreous cavity injection of Compazine in the treatment of proliferative diabetic retinopathy.Methods A total of 66 patients with proliferative diabetes retinopathy admitted to Shuyang Hospital from March 2020 to October 2022 were selected as the research objects.They were randomly divided into two groups by the method of random number table.The control group(33 cases)were treated with minimally invasive vitrectomy.The observation group(33 cases)received a combination of drug injection(Conbercept intravitreal injection)on the basis of the control group.Compare two groups of eye indicators and perioperative clinical indicators.Results Before treatment,there was no statistically significant difference in visual acuity,intraocular pressure,and macular fovea thickness between the two groups of patients(P>0.05).After treatment,the eye indicators of both groups improved compared to before treatment,and the observation group showed significant differences in visual acuity,decreased intraocular pressure,and decreased macular fovea thickness compared to the control group(P<0.05).The observation group patients had less time and amount of bleeding during surgery,postoperative edema absorption,fundus hemorrhage absorption,and exudate absorption than the control group,with statistically significant differences(P<0.05).Conclusion For patients with proliferative diabetic retinopathy after the combined program,i.e.,minimally invasive vitrectomy with the intravitreal injection of drugs(Compazine),the efficacy of the treatment is certain,and can effectively promote the recovery of the patient's visual acuity and regulation of intraocular pressure,which is worthy of use and promotion.